株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

眼痛:パイプライン分析

Ocular Pain - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200471
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
眼痛:パイプライン分析 Ocular Pain - Pipeline Review, H2 2016
出版日: 2016年08月31日 ページ情報: 英文 70 Pages
概要

眼痛は目の表面で発生します。通常は異物による刺激や感染症、外傷により発症します。主な症状として、羞明や膿汁の排出(無色または濃色)、視野の縮小、頭痛、結膜炎などが挙げられます。主な治療法には、抗生物質や抗ヒスタミン剤、コルチコステロイドなどが含まれています。

当レポートでは、世界各国での眼痛(Ocular Pain)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

眼痛の概要

治療薬の開発

  • 眼痛向けパイプライン製品:概要
  • 眼痛向けパイプライン製品:比較分析

各企業で開発中の眼痛治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

眼痛治療薬:開発中の製品の一覧(企業別)

眼痛治療薬の開発に従事している企業

  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sylentis S.A.U.
  • Valeant Pharmaceuticals International, Inc.

眼痛:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (ブロムフェナクナトリウム + デキサメタゾン酢酸エステル)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • デキサメタゾン酢酸エステル SR
  • ジフルプレドナート XR
  • ISV-303
  • ケトロラクトロメタミン
  • エタボン酸ロテプレドノール
  • 次世代エタボン酸ロテプレドノール
  • NT-71
  • NT-72
  • omaveloxolone
  • RX-10045
  • 疼痛・掻痒症向け NaV1.7 チャネル遮断小分子
  • SYL-1001

眼痛治療薬:最新の薬剤プロファイル

眼痛治療薬:開発が休止状態の製品

眼痛関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8414IDB

Summary

Global Markets Direct's, 'Ocular Pain - Pipeline Review, H2 2016', provides an overview of the Ocular Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ocular Pain
  • The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects
  • The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ocular Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ocular Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ocular Pain Overview
  • Therapeutics Development
    • Pipeline Products for Ocular Pain - Overview
  • Ocular Pain - Therapeutics under Development by Companies
  • Ocular Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ocular Pain - Products under Development by Companies
  • Ocular Pain - Companies Involved in Therapeutics Development
    • D. Western Therapeutics Institute, Inc.
    • InSite Vision Incorporated
    • Kala Pharmaceuticals, Inc.
    • Ocular Therapeutix, Inc.
    • Reata Pharmaceuticals, Inc.
    • Sylentis S.A.U.
    • Valeant Pharmaceuticals International, Inc.
  • Ocular Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bromfenac sodium + dexamethasone acetate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bromfenac sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Ocular Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISV-705 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketorolac tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • loteprednol etabonate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • loteprednol etabonate next generation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-71 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-72 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omaveloxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RX-10045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ocular Pain - Dormant Projects
  • Ocular Pain - Product Development Milestones
    • Featured News & Press Releases
      • Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite
      • Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
      • Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit
      • Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite
      • Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery
      • May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
      • Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite
      • Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
      • Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
      • Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
      • Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
      • Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery
      • Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling
      • Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ocular Pain, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Ocular Pain - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016
  • Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2016
  • Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Ocular Pain - Pipeline by Sylentis S.A.U., H2 2016
  • Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ocular Pain - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Ocular Pain, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top